Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Stock Short Interest Jumps 187.8%

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) saw a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 400 shares, an increase of 187.8% from the August 31st total of 139 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.

Basilea Pharmaceutica Price Performance

Shares of BPMUF remained flat at $77.40 during trading hours on Monday. The company has a quick ratio of 4.68, a current ratio of 5.11 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $71.07 and a 200 day moving average price of $67.93. Basilea Pharmaceutica has a 1-year low of $59.29 and a 1-year high of $77.40.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica Ltd. is a Swiss biopharmaceutical company focused on developing and commercializing medicines for serious bacterial and fungal infections, as well as selected oncology applications. The company was established in 2000 as a spin-off from Roche and is headquartered in Basel, Switzerland.

Basilea’s commercial portfolio includes Cresemba (isavuconazole), an antifungal used to treat invasive aspergillosis and invasive mucormycosis, and Zevtera (ceftobiprole), a cephalosporin antibiotic used for certain serious bacterial infections.